To study the efficacy of a single intravitreal injection of expansile gas as a valuable alternative to current treatment options (conservative, pharmacological, and surgical) in patients with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Hyaloid adhesion occurs regularly in ...

An enzyme injected into the vitreous cavity in patients with vitreomacular adhesion may release focal points of contact, thus obviating the need for surgical intervention for relief of vitreomacular ...

- Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for Vitrectomy ThromboGenics NV (Euronext Brussels ...

ThromboGenics announced data from two Phase 3 clinical trials evaluating ocriplasmin for the treatment of vitreomacular traction (VMT) and macular holes. The studies highlight that a single ...

Vitreomacular adhesion (VMA) can lead to reduced visual acuity, metamorphopsia, photopsia, and micropsia. These symptoms are explained by vitreomacular traction (VMT) at the vitreomacular junction.

Vitreomacular adhesion can lead to pathologic traction and macular hole. The standard treatment for severe, symptomatic vitreomacular adhesion is vitrectomy. Ocriplasmin is a recombinant protease with ...

The composition of vitreous is 98% water and 2% structural macromolecules. Early in embryonic development, the molecular constituents of vitreous form a clear, gel-like structure that is adherent to ...

LEUVEN, Belgium, December 4, 2007 -- - Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for ...

Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole One-time intravitreal injection of Jetrea has shown efficacy in the ...

Stalmans et al. (Aug. 16 issue) 1 report that intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes. It was associated ...